What does the evidence show about Agmatine sulfate's effects?

Read Off Label rates the evidence for Agmatine sulfate as Weak and the benefit magnitude as med, producing an overall grade of C (4.9/10). Keynan 2010 MDD open-label showed response.

What safety findings are reported for Agmatine sulfate?

Agmatine sulfate has a low-med risk profile in the database. Low-Med (GI, possible GH elevation) Legal status: OTC.

Rankings / Cognitive

Agmatine sulfate

Cognitive · Neuromodulator (decarboxylated arginine)

Tier C

Reviewed by Read Off Label · Last reviewed Jun 8, 2026 · How we grade

nmda-modulatorotc

4.9 / 10

Tier C

Ev 3 Bn 5 Sf 7

Bottom line

Read Off Label grades Agmatine sulfate as C (4.9/10) based on weak evidence, med benefit magnitude, and a low-med-risk safety profile.

Keynan 2010 MDD open-label showed response.

Studied, labeled, or reported-use context: 1-3 g/day PO divided, empty stomach — OTC; not individualized guidance.

What the evidence says

Keynan 2010 MDD open-label showed response. Limited controlled human trials. Stacks often include for neuropathic pain and mood. Stomach upset is common; fasting administration appears in consumer protocols but comparative tolerability evidence is limited.

Mechanism

Endogenous neuromodulator; imidazoline I1/I2 receptor agonist; NMDA antagonism; nitric oxide synthase inhibition; proposed mood/anxiety and neuropathic pain effects

Studied, labeled, or reported dose & route

1-3 g/day PO divided, empty stomach

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Agmatine sulfate's effects?: Read Off Label rates the evidence for Agmatine sulfate as Weak and the benefit magnitude as med, producing an overall grade of C (4.9/10). Keynan 2010 MDD open-label showed response.
What safety findings are reported for Agmatine sulfate?: Agmatine sulfate has a low-med risk profile in the database. Low-Med (GI, possible GH elevation) Legal status: OTC.
What doses or routes are reported for Agmatine sulfate?: 1-3 g/day PO divided, empty stomach This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Agmatine sulfate work?: Endogenous neuromodulator; imidazoline I1/I2 receptor agonist; NMDA antagonism; nitric oxide synthase inhibition; proposed mood/anxiety and neuropathic pain effects

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.